Recurrence of Differentiated Thyroid Carcinoma During Full TSH Suppression: Is the Tumor Now Thyroid Hormone Dependent?

Paul J. Davis, Aleck Hercbergs, Mary K. Luidens, Hung Yun Lin

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Well-standardized primary treatment and long-term management of differentiated thyroid carcinoma (DTC) include lowering or suppression of host thyrotropin (TSH) with exogenous L-thyroxine (T4). This treatment recognizes the trophic action of TSH on DTC cells. Suppression of endogenous TSH with T4 is continued in recurrent disease. However, T4 can induce proliferation of follicular and papillary thyroid carcinoma cell lines and of other human carcinoma cells. The proliferative mechanism is initiated at a cell surface receptor for T4 on integrin αvβ3, a receptor by which the hormone also inhibits p53-dependent apoptosis in tumor cells. In recurrent DTC with satisfactory suppression of endogenous TSH, we discuss here the possibility that the tumor is no longer TSH dependent and that T4 has become a critical growth factor for the cancer.

Original languageEnglish
Pages (from-to)7-12
Number of pages6
JournalHormones and Cancer
Volume6
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Thyroid Hormones
Thyroid Neoplasms
Recurrence
Follicular Adenocarcinoma
Neoplasms
Cell Surface Receptors
Thyrotropin
Thyroxine
Integrins
Intercellular Signaling Peptides and Proteins
Hormones
Apoptosis
Carcinoma
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Cite this

Recurrence of Differentiated Thyroid Carcinoma During Full TSH Suppression : Is the Tumor Now Thyroid Hormone Dependent? / Davis, Paul J.; Hercbergs, Aleck; Luidens, Mary K.; Lin, Hung Yun.

In: Hormones and Cancer, Vol. 6, No. 1, 2014, p. 7-12.

Research output: Contribution to journalReview article

@article{2a5384e569e8483f82598a8a1c3858fd,
title = "Recurrence of Differentiated Thyroid Carcinoma During Full TSH Suppression: Is the Tumor Now Thyroid Hormone Dependent?",
abstract = "Well-standardized primary treatment and long-term management of differentiated thyroid carcinoma (DTC) include lowering or suppression of host thyrotropin (TSH) with exogenous L-thyroxine (T4). This treatment recognizes the trophic action of TSH on DTC cells. Suppression of endogenous TSH with T4 is continued in recurrent disease. However, T4 can induce proliferation of follicular and papillary thyroid carcinoma cell lines and of other human carcinoma cells. The proliferative mechanism is initiated at a cell surface receptor for T4 on integrin αvβ3, a receptor by which the hormone also inhibits p53-dependent apoptosis in tumor cells. In recurrent DTC with satisfactory suppression of endogenous TSH, we discuss here the possibility that the tumor is no longer TSH dependent and that T4 has become a critical growth factor for the cancer.",
author = "Davis, {Paul J.} and Aleck Hercbergs and Luidens, {Mary K.} and Lin, {Hung Yun}",
year = "2014",
doi = "10.1007/s12672-014-0204-z",
language = "English",
volume = "6",
pages = "7--12",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "1",

}

TY - JOUR

T1 - Recurrence of Differentiated Thyroid Carcinoma During Full TSH Suppression

T2 - Is the Tumor Now Thyroid Hormone Dependent?

AU - Davis, Paul J.

AU - Hercbergs, Aleck

AU - Luidens, Mary K.

AU - Lin, Hung Yun

PY - 2014

Y1 - 2014

N2 - Well-standardized primary treatment and long-term management of differentiated thyroid carcinoma (DTC) include lowering or suppression of host thyrotropin (TSH) with exogenous L-thyroxine (T4). This treatment recognizes the trophic action of TSH on DTC cells. Suppression of endogenous TSH with T4 is continued in recurrent disease. However, T4 can induce proliferation of follicular and papillary thyroid carcinoma cell lines and of other human carcinoma cells. The proliferative mechanism is initiated at a cell surface receptor for T4 on integrin αvβ3, a receptor by which the hormone also inhibits p53-dependent apoptosis in tumor cells. In recurrent DTC with satisfactory suppression of endogenous TSH, we discuss here the possibility that the tumor is no longer TSH dependent and that T4 has become a critical growth factor for the cancer.

AB - Well-standardized primary treatment and long-term management of differentiated thyroid carcinoma (DTC) include lowering or suppression of host thyrotropin (TSH) with exogenous L-thyroxine (T4). This treatment recognizes the trophic action of TSH on DTC cells. Suppression of endogenous TSH with T4 is continued in recurrent disease. However, T4 can induce proliferation of follicular and papillary thyroid carcinoma cell lines and of other human carcinoma cells. The proliferative mechanism is initiated at a cell surface receptor for T4 on integrin αvβ3, a receptor by which the hormone also inhibits p53-dependent apoptosis in tumor cells. In recurrent DTC with satisfactory suppression of endogenous TSH, we discuss here the possibility that the tumor is no longer TSH dependent and that T4 has become a critical growth factor for the cancer.

UR - http://www.scopus.com/inward/record.url?scp=84925533845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925533845&partnerID=8YFLogxK

U2 - 10.1007/s12672-014-0204-z

DO - 10.1007/s12672-014-0204-z

M3 - Review article

C2 - 25292307

AN - SCOPUS:84925533845

VL - 6

SP - 7

EP - 12

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 1

ER -